Skip to main content
Premium Trial:

Request an Annual Quote

TM Bioscience Secures $14.8 Million Investment

Premium

TORONTO--TM Bioscience, a DNA products company here, has closed a private placement with aggregate gross proceeds of $14,777,000. More than 13 million special warrants were issued and sold through an underwritten private placement by Yorkton Securities for proceeds of $10,477,000. Canadian Medical Discoveries purchased the remaining special warrants for proceeds of $4.3 million. TM Biosciences des igns, develops, and commercializes DNA products for medical diagnostics, therapeutics, biochips, functional genomics, and bioinformatics.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.